if FDA-approved, would be the first prescription medication
indicated for MC. Additional formulations of berdazimer are
in clinical development for other dermatologic and infectious
diseases.
DISCLOSURES
Dr Cartwright, Dr Maeda-Chubachi, and Ms. Enloe are
employees of and stockholders in Novan, Inc. Dr Cartwright is a
former employee of Cassiopea Inc. Funding of this manuscript
and conduct of the clinical trial was funded by Novan, Inc. Dr
Stripling was a study investigator and has received consulting
fees from Novan, Inc.
ACKNOWLEDGMENT
The authors are grateful to the patients and caregivers who gave
the gift of clinical research participation. In addition, we thank all
investigators and study site personnel for their contributions.
Medical writing assistance was provided by Dana L. Randall,
MS, PharmD, Intuitive Graphite, Inc; and funded by Novan, Inc.
REFERENCES
1. Meza-Romero R, Navarrete-Dechent C, Downey C. Molluscum contagiosum: an update and review of new perspectives in etiology, diagnosis, and treatment. Clin Cosmet Investig Dermatol. 2019;12:373-381. doi:10.2147/ CCID.S187224
2. Global molluscum contagiosum epidemiology forecast to 2028. https://www. businesswire.com/news/home/20191216005378/en/Global-Molluscum- Contagiosum-Epidemiology-Forecast-to-2028-ResearchAndMarkets.com. Accessed March 3, 2022.
3. van der Wouden JC, van der Sande R, Kruithof EJ, Sollie A, van Suijlekom- Smit LW, Koning S. Interventions for cutaneous molluscum contagiosum. Cochrane Database Syst Rev. 2017;5(5):CD004767.
4. Basdag H, Rainer BM, Cohen BA. Molluscum contagiosum: to treat or not to treat? Experience with 170 children in an outpatient clinic setting in the northeastern United States. Pediatr Dermatol. 2015;32(3):353-357.
5. Donald JA. Cameron MS. Subchapter 134A - Nitric oxide. In: Ando H, Ukena K, Nagata N, eds. Handbook of Hormones 2nd ed. New York NY: Academic Press. 2021:1083-1086, https://www.sciencedirect.com/science/article/pii/ B9780128206492003016
6. Banerjee NS, Moore DW, Wang HK, Broker TR, Chow LT. NVN1000, a novel nitric oxide-releasing compound, inhibits HPV-18 virus production by interfering with E6 and E7 oncoprotein functions. Antiviral Res. 2019;170:104559.
7. Maeda-Chubachi T, Hebert D, Messersmith E, Siegfried EC. SB206, a nitric oxide-releasing topical medication, induces the beginning of the end sign and molluscum clearance. JID Innov. 2021;1(3):100019.
8. Browning JC, Cartwright M, Hebert A, Paller AS, Hebert D, Kowalewski EK, Maeda-Chubachi T. Efficacy and safety of topical nitric oxide releasing berdazimer gel in patients with molluscum contagiosum: a phase 3 randomized clinical trial. JAMA Dermatol. 2002 Aug 1;158(8):871-878. doi: 10.1001/jamadermatol.2022.2721.
2. Global molluscum contagiosum epidemiology forecast to 2028. https://www. businesswire.com/news/home/20191216005378/en/Global-Molluscum- Contagiosum-Epidemiology-Forecast-to-2028-ResearchAndMarkets.com. Accessed March 3, 2022.
3. van der Wouden JC, van der Sande R, Kruithof EJ, Sollie A, van Suijlekom- Smit LW, Koning S. Interventions for cutaneous molluscum contagiosum. Cochrane Database Syst Rev. 2017;5(5):CD004767.
4. Basdag H, Rainer BM, Cohen BA. Molluscum contagiosum: to treat or not to treat? Experience with 170 children in an outpatient clinic setting in the northeastern United States. Pediatr Dermatol. 2015;32(3):353-357.
5. Donald JA. Cameron MS. Subchapter 134A - Nitric oxide. In: Ando H, Ukena K, Nagata N, eds. Handbook of Hormones 2nd ed. New York NY: Academic Press. 2021:1083-1086, https://www.sciencedirect.com/science/article/pii/ B9780128206492003016
6. Banerjee NS, Moore DW, Wang HK, Broker TR, Chow LT. NVN1000, a novel nitric oxide-releasing compound, inhibits HPV-18 virus production by interfering with E6 and E7 oncoprotein functions. Antiviral Res. 2019;170:104559.
7. Maeda-Chubachi T, Hebert D, Messersmith E, Siegfried EC. SB206, a nitric oxide-releasing topical medication, induces the beginning of the end sign and molluscum clearance. JID Innov. 2021;1(3):100019.
8. Browning JC, Cartwright M, Hebert A, Paller AS, Hebert D, Kowalewski EK, Maeda-Chubachi T. Efficacy and safety of topical nitric oxide releasing berdazimer gel in patients with molluscum contagiosum: a phase 3 randomized clinical trial. JAMA Dermatol. 2002 Aug 1;158(8):871-878. doi: 10.1001/jamadermatol.2022.2721.
AUTHOR CORRESPONDENCE
Tomoko Maeda-Chubachi MD PhD MBA tmaeda-chubachi@novan.com
